PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy
暂无分享,去创建一个
L. Cozzi | A. Santoro | A. Chiti | M. Sollini | L. Antunovic | M. Kirienko | A. Sagona | C. Tinterri | R. de Sanctis | R. Torrisi | R. Zelic
[1] Yemi Kim,et al. Predicting neo‐adjuvant chemotherapy response and progression‐free survival of locally advanced breast cancer using textural features of intratumoral heterogeneity on F‐18 FDG PET/CT and diffusion‐weighted MR imaging , 2019, The breast journal.
[2] V. Goh,et al. Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUVmax in [18F]fluoride and [18F]FDG PET? , 2018, Molecular Imaging and Biology.
[3] YingJian Zhang,et al. Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. , 2018, The oncologist.
[4] N S El Saghir,et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] B. Kaufman,et al. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort. , 2018, Breast.
[6] A. Alavi,et al. Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application. , 2018, PET clinics.
[7] V. Pérez-García,et al. Intratumoral heterogeneity in 18F-FDG PET/CT by textural analysis in breast cancer as a predictive and prognostic subrogate , 2018, Annals of Nuclear Medicine.
[8] S. Dhesy-Thind,et al. Clinical practice guidelines in breast cancer. , 2018, Current oncology.
[9] Vivek Verma,et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy , 2018, Breast Cancer Research and Treatment.
[10] D. Groheux,et al. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[11] Walter Noordzij,et al. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging 18F-FDG PET Imaging Biomarkers in Patients with Esophageal Cancer. , 2018, Radiology.
[12] N. Houssami,et al. Rapid review: radiomics and breast cancer , 2018, Breast Cancer Research and Treatment.
[13] D. Molina,et al. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline 18F-FDG PET/CT in breast cancer with neoadjuvant chemotherapy indication. , 2017, Revista espanola de medicina nuclear e imagen molecular.
[14] Isabella Castiglioni,et al. [18F]FDG PET/CT features for the molecular characterization of primary breast tumors , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[15] H. Tesch,et al. Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project , 2017, Breast Cancer Research and Treatment.
[16] S. Bae,et al. Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013 , 2017, Nuclear Medicine and Molecular Imaging.
[17] D. Groheux,et al. Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[18] Steffen Löck,et al. Image biomarker standardisation initiative - feature definitions , 2016, ArXiv.
[19] A. G. García Vicente,et al. Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach. , 2016, Revista espanola de medicina nuclear e imagen molecular.
[20] Yemi Kim,et al. Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ , 2015, European Radiology.
[21] K. Kitajima,et al. Association between 18F-FDG uptake and molecular subtype of breast cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[22] M. Dank,et al. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer , 2015, Nuclear medicine communications.
[23] Wayne Rochester,et al. IMOS National Reference Stations: A Continental-Wide Physical, Chemical and Biological Coastal Observing System , 2014, PloS one.
[24] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[25] S. Son,et al. Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast , 2014, BMC Cancer.
[26] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[27] M. Soussan,et al. Relationship between Tumor Heterogeneity Measured on FDG-PET/CT and Pathological Prognostic Factors in Invasive Breast Cancer , 2014, PloS one.
[28] Won Hwa Kim,et al. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes , 2014, European Radiology.
[29] S. Kurata,et al. The relationship between 18F-FDG metabolic volumetric parameters and clinicopathological factors of breast cancer , 2013, Nuclear medicine communications.
[30] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Tapio Salakoski,et al. A comparison of AUC estimators in small-sample studies , 2009, MLSB.
[32] Patrick Royston,et al. How should variable selection be performed with multiply imputed data? , 2008, Statistics in medicine.
[33] Luigi Salmaso,et al. Model performance analysis and model validation in logistic regression , 2007 .
[34] E Provenzano,et al. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy , 2007, Histopathology.
[35] T. Stijnen,et al. Review: a gentle introduction to imputation of missing values. , 2006, Journal of clinical epidemiology.
[36] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[37] J. Hanley,et al. The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.
[38] A. Tutt,et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.
[39] A. G. García Vicente,et al. Molecular subtypes of breast cancer: metabolic correlation with 18F-FDG PET/CT , 2013, European journal of nuclear medicine and molecular imaging.